Clinical Trial Update: A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of siltuximab in men with metastatic castration-resistant prostate cancer was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Cancer, Prostate | Phase 2 | Status: TERMINATED | Results posted: 2014-06-12